Observational studyOpen heart2026
Treatment and control of low-density lipoprotein for primary prevention in patients in Wales with and without depression: a study of whole-population electronic health records.
Observational study in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study investigated the influence of depression status on lipid lowering therapy (LLT) prescribing and achievement of guideline targets for low density lipoprotein cholesterol (LDL-C) levels in patients after first documentation of a high risk of developing atherosclerotic cardiovascular disease (ASCVD). Associations with sex, socioeconomic status and location of residence on these relationships were also explored.
methodsA retrospective observational cohort study (2010-2019) using individual-level linked, anonymised, routinely collected electronic health record data sources. Patients with/without depression and documentation of a high global QRISK risk score (HQR) were included. Outcome variables were LLT prescription within 6 months of HQR documentation and recording of LDL-C level within European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) targets and achievement of >40% reduction in LDL-C according to National Institute for Health and Care Excellence guidance within 1 year of HQR. Logistic regression analysis explored the association between depression and outcome variables adjusting for sex, age group, deprivation, location of residence and other risk factors.
resultsQRISK was documented in 284 859 (12.8%) patients. In the 103 340 HQR patients, depression (identified pre-HQR or post-HQR documentation) was associated with a higher likelihood of LLT prescription (pre-OR 1.15, 95% CI 1.08 to 1.23; post-OR 1.39, 95% CI 1.19 to 1.64). Depression was not associated with achievement of LDL-C control as per EAS/ESC guidelines (<2.6 mmol/L; pre-OR 1.10, 95% CI 1.00 to 1.23; post-OR 1.00, 95% CI 0.79 to 1.28). Depression pre-HQR was associated with achievement of a >40% reduction in LDL-C (pre-OR 1.16, 95% CI 1.02 to 1.32; post-OR 0.94, 95% CI 0.70 to 1.25)
conclusionOnly a small proportion of patients had a documented QRISK score in their record. While high ASCVD risk patients with depression were more likely to be prescribed LLT, this was not necessarily associated with better LDL-C control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.